Abstract Number: 1221 • 2014 ACR/ARHP Annual Meeting
Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent
Background/Purpose Hyperuricemia is particularly common in patients with chronic kidney disease (CKD). Its role, however, as a risk factor for renal outcomes of CKD is…Abstract Number: 1214 • 2014 ACR/ARHP Annual Meeting
Oxidative Stress from Use of Allopurinol – Is There a Reason for Patients with Gout to Take Vitamin C?
Background/Purpose During acute gout attacks neutrophils are activated and release a number of pro-inflammatory cytokines and enzymes. One of these enzymes is myeloperoxidase (MPO), which…Abstract Number: 1220 • 2014 ACR/ARHP Annual Meeting
Higher Inflammatory Response in Elderly Patients during Gout Attack
Higher inflammatory response in elderly patients during gout attack Background/Purpose Clinical experiences suggest that gout attacks in elderly patients are accompanied by stronger systemic inflammatory…Abstract Number: 1219 • 2014 ACR/ARHP Annual Meeting
Lack of Gene-Diuretic Interactions on Risk of Incident Gout: The Nurses’ Health Study and Health Professionals Follow-up Study
Background/Purpose: Diuretics, particularly thiazide and loop diuretics, increase the risk of gout, likely through urate transporters (e.g., OAT4) and volume depletion promoting urate reabsorption. As…Abstract Number: 1217 • 2014 ACR/ARHP Annual Meeting
The Random Urine Uric Acid to Creatinine Ratio As a Predictor of 24-Hour Urine Uric Acid Excretion in Gout Patients
Background/Purpose: Gout is an inflammatory disease resulted from an increased body pool of uric acid. The measurement of 24-hour uric acid excretion is important to…Abstract Number: 1216 • 2014 ACR/ARHP Annual Meeting
The Relationship Between Serum Homocysteine, Uric Acid and Renal Function in Chronic Gouty Patients: 2 Year Follow-up Results
Background/Purpose: Hyperhomocysteinemia is one of the important factors for the endothelial cell damage and also a risk factor for cardiovascular events. Gout is known to…Abstract Number: 1215 • 2014 ACR/ARHP Annual Meeting
Circulating Mediators of Bone Remodeling in Patients with Tophaceous Gout
Background/Purpose: Disordered bone remodeling has been implicated in the development of bone erosion in tophaceous gout. The function of bone cells in the skeleton is…Abstract Number: 1165 • 2014 ACR/ARHP Annual Meeting
Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Background/Purpose: Gout affects approximately 1-4% of the population in developed Western countries. The hallmark signs of gout are elevated serum uric acid (SUA) level, episodes…Abstract Number: 1155 • 2014 ACR/ARHP Annual Meeting
Economic Impact of Frequent Gout Flares in a Managed Care Setting
Background/Purpose Gout is the most common inflammatory arthritis in the US. For most patients, excruciatingly painful gout attacks (“flares”) are the major clinical burden of…Abstract Number: 927 • 2014 ACR/ARHP Annual Meeting
Urate Crystal Induced Inflammation and Joint Pain Are Reduced in Transient Receptor Potential Ankyrin 1 (TRPA1) Deficient Mice – a New Potential Role for TRPA1 in Gout
Background/Purpose: In the gout, monosodium urate (MSU) crystals deposit intra-articularly and cause painful arthritis. In the present study we tested the hypothesis that Transient Receptor…Abstract Number: 901 • 2014 ACR/ARHP Annual Meeting
Rate of Serum Uric Acid (SUA) Assessment in Gout Patients Treated with Urate-Lowering Therapy: Treating to Target?
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by chronic hyperuricemia, leading to urate crystal deposition disease and subsequent intermittent…Abstract Number: 888 • 2014 ACR/ARHP Annual Meeting
Annual Medical Care Expenditures Among US Adults with Gout, 2005 – 2011
Background/Purpose: Costs associated with gout are of growing interest due to its increasing prevalence, but quantifying those costs has been hampered by its co-occurrence with…Abstract Number: 831 • 2014 ACR/ARHP Annual Meeting
Bisphosphonates and Risk of Acute Pseudogout: A Case-Control Study in the Clinical Practice Research Datalink (CPRD)
Background/Purpose: Acute pseudogout is the most dramatic clinical manifestation of calcium pyrophosphate crystal deposition (CPPD). CPPD is most commonly sporadic and age-related but can rarely…Abstract Number: 828 • 2014 ACR/ARHP Annual Meeting
Extent of Urate Deposition in Asymptomatic Hyperuricemia and Symptomatic Gout: A Dual Energy Computed Tomography Study
Background/Purpose: Recent studies have reported that ultrasound features of urate crystal deposition are present in some asymptomatic individuals with hyperuricemia, suggesting that subclinical urate deposition…Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »